355 related articles for article (PubMed ID: 33376178)
1. Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.
Jeon HL; Lee H; Yoon D; Lee Y; Kim JH; Jee D; Shin JY
BMJ Open; 2020 Dec; 10(12):e042484. PubMed ID: 33376178
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.
Emami-Naeini P; Garmo V; Boucher N; Fernando R; Menezes A
Ophthalmol Retina; 2024 Apr; 8(4):388-398. PubMed ID: 37866681
[TBL] [Abstract][Full Text] [Related]
4. Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study.
Lee WA; Shao SC; Liao TC; Lin SJ; Lai CC; Lai EC
BioDrugs; 2022 Mar; 36(2):205-216. PubMed ID: 35230656
[TBL] [Abstract][Full Text] [Related]
5. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Holekamp N; Gentile B; Giocanti-Aurégan A; García-Layana A; Peto T; Viola F; Kertes PJ; Mirt M; Kotecha A; Lambert J; Lewis HB; Chi GC
Ophthalmic Res; 2024; 67(1):311-321. PubMed ID: 38679018
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database.
Kawasaki R; Bauer M; Bezlyak V; Ogura Y
Jpn J Ophthalmol; 2021 Mar; 65(2):215-226. PubMed ID: 33420855
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.
Voutsas NT; Papageorgiou E; Tantou A; Dimitriou VA; Tsironi EE; Kotoula M
Int Ophthalmol; 2022 Sep; 42(9):2673-2684. PubMed ID: 35416615
[TBL] [Abstract][Full Text] [Related]
10. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
11. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
12. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
[TBL] [Abstract][Full Text] [Related]
13. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
VanderBeek BL; Scavelli K; Yu Y
Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
[TBL] [Abstract][Full Text] [Related]
14. Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study).
Gascon P; Borget I; Comet A; Carton L; Matonti F; Dupont-Benjamin L
Eur J Ophthalmol; 2022 May; 32(3):1702-1709. PubMed ID: 34284605
[TBL] [Abstract][Full Text] [Related]
15. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
17. Real world evidence of use of anti-VEGF therapy in Denmark.
Vorum H; Olesen TK; Zinck J; Størling Hedegaard M
Curr Med Res Opin; 2016 Dec; 32(12):1943-1950. PubMed ID: 27494692
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal antivascular endothelial growth factor in diabetic macular oedema: scoping review of clinical practice guidelines recommendations.
Vargas-Peirano M; Verdejo C; Vergara-Merino L; Loézar C; Hoehmann M; Pérez-Bracchiglione J
Br J Ophthalmol; 2023 Mar; 107(3):313-319. PubMed ID: 34906962
[TBL] [Abstract][Full Text] [Related]
19. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.
Tetikoğlu M; Yüksel Z; Aktas S; Sağdik HM; Özcura F
Int Ophthalmol; 2018 Dec; 38(6):2381-2388. PubMed ID: 29030794
[TBL] [Abstract][Full Text] [Related]
20. Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema.
Mandava NK; Kuriyan AE; Ho AC; Hsu J; Regillo CD; Klufas MA
Curr Opin Ophthalmol; 2024 May; 35(3):197-204. PubMed ID: 38345051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
